Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.49 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 11/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230063 | 0.91 | ABL1 (0.48) | MAP2K4MAPK1MAPK6MAPKAPK5GSK3B | |
| SCHEMBL4225132 | 0.89 | MAP2K4 (0.47) | MAP2K4MAPK1MAPK6DDR2FGFR1 | |
| SCHEMBL4220579 | 0.86 | MAPK1 (0.42) | MAP2K4MAPK1DDR2FGFR1TRPA1 | |
| SCHEMBL14098861 | 0.84 | MAPK14 (0.44) | MAPK1GSK3BHDAC6CYP2C9MAPK14 | |
| SCHEMBL4219380 | 0.84 | MAPK1 (0.52) | MAPK1 | |
| SCHEMBL4228198 | 0.84 | MAP2K4 (0.45) | MAP2K4MAPK1MAPK6GSK3BTRPA1 | |
| SCHEMBL4219360 | 0.84 | GSK3B (0.46) | MAP2K4MAPK1GSK3B | |
| SCHEMBL4215057 | 0.84 | MAPK14 (0.43) | MAPK1GSK3BHDAC6CYP2C9MAPK14 | |
| SCHEMBL3522651 | 0.84 | MAPK14 (0.43) | MAPK1GSK3BHDAC6CYP2C9MAPK14 | |
| SCHEMBL4222889 | 0.83 | LRRK2 (0.40) | MAP2K4MAPK1DDR2FGFR1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK7 | MAP2K4 54/4885MAPK1 1/4885MAPK6 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.